A niche blog dedicated to the issues that arise when supplementary protection certificates (SPCs) extend patents beyond their normal life -- and to the respective positions of patent owners, investors, competitors and consumers. The blog also addresses wider issues that may be of interest or use to those involved in the extension of patent rights. You can email The SPC Blog here
Wednesday, 10 August 2011
Uncertainty and disharmony: an overview
In an article, "Uncertainty and Disharmony Plague Patent Term Extensions in Europe" (published today by Genetic Engineering & Biotechnology News), Andrew Sharples discusses the problems created by insufficiently specific and variously-implemented EU legislation which was intended to harmonise the law and practice relating to patent term extensions. He gives a short overview of the issues currently awaiting decision by the Court of Justice of the European Union, as well as the issues surrounding the controversial 'infringement test'.
Labels:
article
Escitalopram decision from Germany -- but no ECJ reference this time
From Chris Hayes (Lundbeck) comes news of another Escitalopram SPC decision, this time from the German Patent Court (you can download it here). An English translation has been promised in due course. Chris explains:
"The case was heard earlier this year, but we have only just received the full reasons for judgment. This was an attack on the SPC only, and the Patent Court's decision is in alignment with the earlier decision of the German Supreme Court on the validity of the basic patent and the SPC.Thanks so much, Chris, for this judgment.
A reference to the ECJ was refused, as the Court decided that this was a purely factual dispute. The Court decided that foreign regulatory proceedings had no bearing on the validity of the SPC;, nor did decisions of the German pricing authorities".
Labels:
escitalopram,
Germany
Monday, 8 August 2011
The fight for atorvastatin: further news
According to a recent piece in Dispensing Doctor, "Teva and Pfizer set the date for Lipitor patent battle: Asda strikes no-involvement deal", by Ailsa Colquhoun, a date in late November has been mooted for the Lipitor patent validity trial due to take place at the High Court of Justice in London [on earlier proceedings in this dispute see here]. If Teva's challenge succeeds, it will be legally entitled to release the generic atorvastatin stock currently held by wholesalers. According to the news item:
"The trial takes place some six months before the scheduled expiry of the current UK patent supplementary protection certificate (SPC) for Lipitor. ...
In the meantime, Pfizer has shown no sign of abating the legal pressure on dispensers. On Friday, July 22, Pfizer announced that it had struck a deal in the High Court to exclude Asda from the ongoing legal action against Teva and other wholesalers, in return for a promise not to deal or dispense generic atorvastatin. However, at the same hearing, Pfizer named Day Lewis in its ongoing action against Teva and others, and has signalled its intention to pursue an injunction and full financial recompense from the chain".
Labels:
atorvastatin,
Lipitor
Friday, 5 August 2011
Medeva and the interpretation of EU law: literal or teleological?
Earlier this week The SPC Blog posted "The holiday is over: a close reading of the Opinion in Medeva", in which Paul Inman expressed some bewilderment as to what precisely the Advocate General was advising the Court of Justice. It seems that Paul is not alone, since the blog has now received a further admission from a reader that this Opinion has caused confusion, this coming from International Patent Consultant Herwig von Morze. Writes Herwig:
Readers' thoughts on Herwig's and Paul's comments are very welcome.
"I share Paul Inman's confusion regarding paras 67-69 of the Advocate General's Opinion in Medeva, in particular since Art.1(c) uses the word "protects". May I add a confusion of my own? I am confused by the fact that the AG uses a literal interpretation for the purpose of rejecting the infringement test as the basis for the assessment of Art. 3(a). However, thereafter in the paras starting with 75, she rejects the literal interpretation essentially of the same articles as in conflict with the aims of the regulation.
I haven't read any ECJ decision or AG Opinion which vacillates between literal interpretation for arriving at one conclusion and teleological interpretation to support the aims of a regulation. Such a selective approach seems arbitrary to me. Perhaps somebody with more ECJ experience can help and set me straight?"My personal recollection is that the ECJ seems to favour starting from the teleological approach in intellectual property references even when its application contradicts the clear and unambiguous literal meaning of plainly expressed words (see eg Case C-292/00 Davidoff v Gofkid). However, as a common lawyer I have no problem with inconsistency between the two approaches since I was brought up to believe that they were complementary rather than in conflict: one started with the literal interpretation and applied it -- unless (i) there was an ambiguity as to how it should be applied or (ii) its application produced a result that was clearly nonsensical, in which case one moved straight away to a teleological approach. The ECJ's approach is fortified by the availability of considerable material that is prepared for the purpose of aiding interpretation of Directives and Regulations, particularly in the form of the recitals in the preamble, whereas domestic statutory interpretation in the United Kingdom does not have such useful guidance, especially in the case of older statutes. However, the Court of Appeal for England and Wales in Neurim must have been wearing teleological spectacles when it viewed the law on SPCs and questuined whether it was "fit for purpose"
Readers' thoughts on Herwig's and Paul's comments are very welcome.
Labels:
ECJ reference,
Medeva
SPC Event 2011 Slides and Videos
Following the successful SPC Blog event in June, we're now able to provide you with embedded videos of the presentations and the Q+A session and a downloadable link to the slidepack (also embedded). This is the first time that we have attempted this, so please let us know if any of the links do not work (the videos may require Internet Explorer to function)!
Introduction video - Robert Stephen
Medeva and All Things Combination: Nicole Jadeja, Rouse
SPC Case Law in Belgium: Patricia Cappuyns, Olswang
SPCs in Spain: Javier Huarte, Grau and Angelo
C-130/11Neurim: Hugh Goodfellow and Ed Oates, Carpmaels and Ransford
Q+ A Session
Introduction video - Robert Stephen
Medeva and All Things Combination: Nicole Jadeja, Rouse
SPC Case Law in Belgium: Patricia Cappuyns, Olswang
SPCs in Spain: Javier Huarte, Grau and Angelo
C-130/11Neurim: Hugh Goodfellow and Ed Oates, Carpmaels and Ransford
Q+ A Session
Labels:
Video Embedded Presentation
Wednesday, 3 August 2011
"Déjà vu at the ECJ?": a note on Neurim
"Déjà vu at the ECJ?" is a Current Intelligence note by patent attorneys Mike Snodin and John Miles (Potter Clarkson LLP, United Kingdom) on Neurim Pharmaceuticals (1991) Ltd v The Comptroller-General of Patents [2011] EWCA Civ 228, 3 February 2011 (on which see The SPC Blog here and here). This note is published in the Journal of Intellectual Property Law & Practice (2011) 6 (8): 513-515. Its salient points are reproduced here:
"The Court of Appeal for England and Wales (CA) has referred questions to the Court of Justice of the European Union (ECJ) on whether a supplementary protection certificate (SPC) can be obtained for active ingredients which have previously been authorized for a different use. Although the ECJ may well feel that it has considered this issue previously, the case again highlights weaknesses of the legislation governing SPCs, and has even prompted the CA to question whether it is fit for purpose.
...
The precise questions referred by the CA have not previously been considered by the ECJ. However, similar factual situations have been the background to earlier references to the ECJ in respect of Pharmacia Italia, MIT and Yissum cases (cases C-31/03, C-431/04 and C-202/05, respectively).
In particular, the Pharmacia Italia case led to the ECJ deciding that an earlier veterinary MA for a formulation containing cabergoline was prejudicial to the grant of a SPC based upon the first MA for a human use of cabergoline. Although the decision in Pharmacia Italia related specifically to the transitional provisions of the legislation (Article 19(1) of Regulation 1768/92), another ECJ decision (case C-127/00, Hässle) has made it clear that the words “first marketing authorisation” must take the same interpretation for all provisions of the SPC legislation.
...
Underlying referral of questions in Neurim appears to be the CA’s perception that there is an injustice in not awarding an SPC to the holder of a patent for a new (and non-obvious) use of a previously authorized substance which is the subject of a new MA. In this respect, it will be interesting to see how the ECJ answers the questions referred. To date, the ECJ has interpreted Article 3(d) in a manner that takes no account of the perceived injustices outlined by the CA. Instead, it has simply adopted a ‘one bite of the cherry’ approach, in which the availability and term of all SPC protection for an active agent is based upon the first MA issued for that active agent (for any human or veterinary use).
....
If Neurim succeeds in persuading the ECJ that Article 4 should be taken into account when interpreting the term ‘first marketing authorization’ in Article 3(d) of Regulation 469/2009, this would significantly increase the number of patents to (approved) second medical uses that might qualify for SPC protection.
Success for Neurim based only on its potentially most persuasive arguments (relating to the regulatory burden faced by those seeking the first ever authorization for a human use of an active agent) would have a more limited impact: the relevance of the decision might be restricted to only those factual situations where the existence of one or more earlier MAs for certain uses does not in any way reduce the regulatory burden for the sponsor of (pre-)clinical trials for a different, separately patented use.
However, it is far from certain that Neurim will succeed in relation to any of its arguments. Success depends upon persuading the ECJ to depart completely from the logic applied in previous ECJ decisions relating to Article 3(d).
In any event, the case will be watched closely by SPC aficionados, as a decision completely adverse to Neurim could lead to questioning whether the legislation is fit for purpose, or even to calls for its complete overhaul".
Labels:
"first authorisation",
ECJ reference
Tuesday, 2 August 2011
The holiday is over: a close reading of the Opinion in Medeva
![]() |
| Will our correspondent be applying for a Supplementary Holiday Certificate ...? |
"Dear SPC Blog
Sorry for harking back to the Medeva AG opinion (but its holiday season and some of us have been away!)
As regards the first question in this reference - what is meant by "the product is protected by a basic patent in force", it seems to me (unless I have missed something) that the AG has -- in rather an off-hand manner -- answered this in passing somewhere around the late 60s (paras).
- In para 67 she makes reference to the "subject matter" of a patent when she states that the subject matter of each of the three categories of patent referred to in Art 1(c) (i.e. product, process and use) is always the "active" [not sure if this is correct -- but anyway].
- In para 68, she then appears simply to proclaim that "the subject matter" of a patent equates to the "extent of protection" of that patent. [So there we have her answer: "protected by a basic patent" = "the subject matter of a basic patent"]. Somewhat bizarrely, she then differentiates this concept of "extent of protection" from "the protective effect" of the basic patent (despite the obvious link in the word "protect" in both phrases). Whilst there may indeed be a distinction between these two concepts, there appears to me to be no reasoning behind her proclamation that "extent of protection" equates to "the subject matter". [and anyway -- what does that mean?]
Looking at this from a wider perspective of the legislation - what does Art. 4 now mean?
- In para 69 she fortifies her position by stating "The decisive consideration in that context is the fact that the definition of the basic patent in Art 1(c) of [the Regulation] takes as its basis the subject matter of the patent, and not its protective effect." (emphasis in original). Again, there seems to be no basis for this statement, despite the fact that Art. 1(c) uses the word "protects" and not "subject matter". Nevertheless, the entire remainder of the Opinion is built on this "rock" of principle - that "protects" in Article 1(c) actually means "is the subject matter of", and "protected by" in Art. 3(a) actually means "the subject matter of".
- That article is entitled "Subject matter of protection". Should this be construed (in the context of this Regulation) as "Subject matter of subject matter"?
- The substance of Art. 4 states: "Within the limits of protection conferred by the basic patent …". Does this therefore mean "Within the subject matter of the basic patent"?
As ever, readers' thoughts and comments are invited.Finally, does this mean we now have to refer to this Regulation as the 'Supplementary Subject Matter Certificate Regulation'?
- Art. 4 goes on: "the protection conferred by a certificate shall extend only to the product …". Does this mean "the subject matter of the certificate shall extend only to the product …"? If that is the case, how does her inference that SPCs for active(s) forming only part of multi-active medicinal products will protect those multi-active medicinal products stack up?
Back from Holiday and Confused".
Labels:
ECJ reference,
Georgetown,
Medeva
Non-payment of Cetrorelix fee on time fatal for SPC
On 20 July 2010 the United Kingdom's Intellectual Property Office issued a decision in Case BL0/252/11 The Administrators of the Tulane Education Fund, on the consequences of the non-payment of the fee for bringing an SPC into effect. The official note of the case describes this decision thus:
"The applicant failed to pay the prescribed fee for bringing supplementary protection certificate SPC/GB/99/033 into effect within the prescribed period or within the period of six months following the end of the prescribed period. The applicant argued that a late payment of the fee should be allowed either as a correction of an irregularity under rule 107 [of the Patents Rules 2007], a reinstatement under section 20A [of the Patents Act 1977], or a restoration under section 28. The hearing officer found that there was no error, default or omission on the part of the Office that resulted in the failure to pay the SPC fee in time in order to bring the SPC into effect and therefore rule 107 did not give the comptroller discretion to allow the late payment. He also found that neither section 20A nor section 28 applied in the present circumstances. The SPC could not therefore be brought into effect".The SPC in this instance was for “Cetrorelix and pharmaceutically acceptable salts thereof, including cetrorelixacetate”, protected by basic patent EP (UK) 0299402 entitled “LHRH antagonists, their manufacture and pharmaceutical compositions thereof”. The circumstances in which the applicant failed to make payment on time are explained in the decision of Mr B. Micklewright.
Labels:
non-payment of fee
Thursday, 28 July 2011
For the sake of completeness, here's the Generics ruling
Also before the Court of Justice of the European Union today was Case C‑427/09, Generics (UK) Ltd v Synaptech Inc., a reference for a preliminary ruling from the Court of Appeal (England and Wales). This time the contested substance was not memantine but galantamine -- which had been on sale as a medicinal product in various European countries for more than 40 years. In central Europe, it was used to treat neuromuscular conditions. In 1963 a marketing authorisation was issued in Austria, under that countty's 1947 medicines regulations, to use galantamine in the treatment of poliomyelitis under the trade mark Nivalin. In Germany, galantamine was already on the market in the 1960s under the same trade mark and, under the German Law of 1976, galantamine could remain on the German market as a product deemed to be authorised as a medicinal product under a ‘fictitious’ authorisation.
In January 1987 Synaptech filed an application for a basic galantamine patent in the European Patent Office, claiming the use of galantamine for the treatment of Alzheimer’s Disease. In 1997 Janssen-Cilag took over distribution of Nivalin in Austria and, in 1999, filed an application in Sweden for a marketing authorisation for the use of galantamine in a medicinal product to treat Alzheimer’s Disease under the brand name Reminyl. After an assessment carried out in accordance with Directive 65/65, Reminyl was authorised in March 2000. Six months later, the United Kingdom also issued a market authorisation for Reminyl.
All good fictions come to an end, and the fictitious authorisation of Nivalin was no exception: the German and Austrian authorisation were withdrawn in the second half of 2000 and in 2001 respectively.
In December 2000 Synaptech applied for a UK SPC for galantamine, listing the Swedish marketing authorisation as the first authorisation to place the product on the market as a medicinal product in the Community. Based on that marketing authorisation, Synaptech's application was granted with a maximum term of five years, expiring in January 2012, with the basic galantamine patent expiring on 16 January 2007.
Generics was not happy about this, taking the view that the SPC’s date of expiry had not been calculated correctly by the UK Patent Office when it chose to rely on the Swedish marketing authorisation. Generics therefore sought rectification under section 34 of the Patents Act 1977. That claim was rejected, so Generics appealed to the Court of Appeal. The company accepted that the German and Austrian marketing authorisations had never complied with the requirements of Directive 65/65 and that the first authorisation that did comply with it was the Swedish authorisation. The Court of Appeal (England and Wales) (Civil Division) had doubts as to the interpretation which should be given to the concept of ‘first authorisation to place the product on the market in the Community’ in Article 13(1) of Regulation 1768/92, so it decided to stay the proceedings and to refer the following questions to the Court of Justice for a preliminary ruling:
In January 1987 Synaptech filed an application for a basic galantamine patent in the European Patent Office, claiming the use of galantamine for the treatment of Alzheimer’s Disease. In 1997 Janssen-Cilag took over distribution of Nivalin in Austria and, in 1999, filed an application in Sweden for a marketing authorisation for the use of galantamine in a medicinal product to treat Alzheimer’s Disease under the brand name Reminyl. After an assessment carried out in accordance with Directive 65/65, Reminyl was authorised in March 2000. Six months later, the United Kingdom also issued a market authorisation for Reminyl.
All good fictions come to an end, and the fictitious authorisation of Nivalin was no exception: the German and Austrian authorisation were withdrawn in the second half of 2000 and in 2001 respectively.
In December 2000 Synaptech applied for a UK SPC for galantamine, listing the Swedish marketing authorisation as the first authorisation to place the product on the market as a medicinal product in the Community. Based on that marketing authorisation, Synaptech's application was granted with a maximum term of five years, expiring in January 2012, with the basic galantamine patent expiring on 16 January 2007.
Generics was not happy about this, taking the view that the SPC’s date of expiry had not been calculated correctly by the UK Patent Office when it chose to rely on the Swedish marketing authorisation. Generics therefore sought rectification under section 34 of the Patents Act 1977. That claim was rejected, so Generics appealed to the Court of Appeal. The company accepted that the German and Austrian marketing authorisations had never complied with the requirements of Directive 65/65 and that the first authorisation that did comply with it was the Swedish authorisation. The Court of Appeal (England and Wales) (Civil Division) had doubts as to the interpretation which should be given to the concept of ‘first authorisation to place the product on the market in the Community’ in Article 13(1) of Regulation 1768/92, so it decided to stay the proceedings and to refer the following questions to the Court of Justice for a preliminary ruling:
‘(1) For the purposes of Article 13(1) of [Regulation No 1768/92], is the “first authorisation to place the product on the market in the Community” the first authorisation to place the product on the market in the Community which was issued in accordance with [Directive 65/65] (now replaced with Directive 2001/83/EC [of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ 2001 L 311, p. 67)]) or will any authorisation that enables the product to be placed on the market in the Community or [European Economic Area] suffice?
(2) If, for the purposes of Article 13(1) of [Regulation No 1768/92], an “authorisation to place the product on the market in the Community” must have been issued in accordance with [Directive 65/65] (now replaced with Directive 2001/83/EC), is an authorisation that was granted in 1963 in Austria in accordance with the national legislation in force at that time (which did not comply with the requirements of [Directive 65/65]) and that was never amended to comply with [that directive] and was ultimately withdrawn in 2001, to be treated as an authorisation granted in accordance with [that directive] for that purpose?’The Court today, in a very short ruling indeed, observed that the answer to these questions is relevant only if galantamine is within the scope of that regulation and can thus be the subject of an SPC. Citing this morning's other SPC in Case C‑195/09 Synthon [2011] (noted here), the Court said Article 2 of Regulation 1768/92 means that a product like galantamine, placed on the market in the Community as a medicinal product for human use before receiving a Directive 65/65 marketing authorisation and without undergoing safety and efficacy testing, was not within the scope of Regulation 1768/92 and could not therefore be the subject of an SPC. Since galantamine couldn't be the subject of an SPC, Articles 13 and 19 of Regulation 1768/92 don't apply. If they don't apply, the Court doesn't need to interpret them.
The ECJ therefore ruled as follows:
"A product, such as that at issue in the main proceedings, which was placed on the market in the European Community as a medicinal product for human use before obtaining a marketing authorisation in accordance with Council Directive 65/65 ... as amended ... may not be the subject of a supplementary protection certificate.".
Labels:
Data for generics,
ECJ reference,
Galantamine
Synthon ruling rejects pre-65/65 authorisations
This morning the Court of Justice of the European Union handed down its ruling in Case C‑195/09 Synthon BV v Merz Pharma GmbH & Co. KGaA, this being a reference for a preliminary ruling from the Patents Court, England and Wales.
To summarise, even before 1 September 1976 Merz was offering memantine for sale in Germany as a medicinal product for human use under the brand name Akatinol. That product, used in the treatment of Parkinson’s Disease and for other indications, was covered by an authorisation issued in accordance with German legislation from 1961 which did not requiere medicinal products to be tested for safety or efficacy. Under the German Law of 1976 memantine was granted a marketing authorisation in Germany without going through the procedures required under Directive 65/65, the first-ever European pharma Directive.
In June 1983 Merz applied to the competent Luxembourg authorities for a marketing authorisation for that medicinal product. This was was issued in September 1983 under a Luxembourg Law of 1983. However, the Luxembourg authorities relied on the German marketing authorisation issued previously and did not test the safety and efficacy of memantine. In April 1989 Merz applied for a European patent for memantine hydrochloride which was granted even though memantine was already available commercially, on the ground that the patent was for a second medical use of memantine: for the preparation of a medicinal product to treat Alzheimer’s Disease. This patent expired on 13 April 2009.
Both the German and Luxembourg marketing authorisations were withdrawn when, in May 2002, a series of marketing authorisations valid within the European Community (‘the 2002 marketing authorisations’) were issued to Lundbeck as a licensee of Merz under Council Regulation 2309/93. This authorisation of 2002 was for the medicinal product Ebixa, the brand name adopted in order to market memantine's second medical use. Before this authorisation was issued, the safety and efficacy of Ebixa had been tested by the European Agency for the Evaluation of Medicinal Products, in accordance with Directive 65/65.
In November 2002 Merz applied to the United Kingdom Patent Office for an SPC for memantine. In its application, Merz referred to the basic patent valid in the UK and also to the 2002 marketing authorisation, but not to the prehistoric German or Luxembourg marketing authorisations. The SPC was granted in August 2003 for a term of five years.
Generics manufacturer Synthon then challenged the validity of Merz's SPC and maintained that, if valid, its term of protection should be fixed at zero. The Patents Court had some doubt both as to the scope of the SPC regulation, Regulation 1768/92, and the definition of ‘first authorisation to place … on the market in the Community’, within the meaning of Articles 13 and 19 of that regulation, it decided to stay the proceedings and to refer the following questions to the Court of Justice for a preliminary ruling:
To summarise, even before 1 September 1976 Merz was offering memantine for sale in Germany as a medicinal product for human use under the brand name Akatinol. That product, used in the treatment of Parkinson’s Disease and for other indications, was covered by an authorisation issued in accordance with German legislation from 1961 which did not requiere medicinal products to be tested for safety or efficacy. Under the German Law of 1976 memantine was granted a marketing authorisation in Germany without going through the procedures required under Directive 65/65, the first-ever European pharma Directive.
In June 1983 Merz applied to the competent Luxembourg authorities for a marketing authorisation for that medicinal product. This was was issued in September 1983 under a Luxembourg Law of 1983. However, the Luxembourg authorities relied on the German marketing authorisation issued previously and did not test the safety and efficacy of memantine. In April 1989 Merz applied for a European patent for memantine hydrochloride which was granted even though memantine was already available commercially, on the ground that the patent was for a second medical use of memantine: for the preparation of a medicinal product to treat Alzheimer’s Disease. This patent expired on 13 April 2009.
Both the German and Luxembourg marketing authorisations were withdrawn when, in May 2002, a series of marketing authorisations valid within the European Community (‘the 2002 marketing authorisations’) were issued to Lundbeck as a licensee of Merz under Council Regulation 2309/93. This authorisation of 2002 was for the medicinal product Ebixa, the brand name adopted in order to market memantine's second medical use. Before this authorisation was issued, the safety and efficacy of Ebixa had been tested by the European Agency for the Evaluation of Medicinal Products, in accordance with Directive 65/65.
In November 2002 Merz applied to the United Kingdom Patent Office for an SPC for memantine. In its application, Merz referred to the basic patent valid in the UK and also to the 2002 marketing authorisation, but not to the prehistoric German or Luxembourg marketing authorisations. The SPC was granted in August 2003 for a term of five years.
Generics manufacturer Synthon then challenged the validity of Merz's SPC and maintained that, if valid, its term of protection should be fixed at zero. The Patents Court had some doubt both as to the scope of the SPC regulation, Regulation 1768/92, and the definition of ‘first authorisation to place … on the market in the Community’, within the meaning of Articles 13 and 19 of that regulation, it decided to stay the proceedings and to refer the following questions to the Court of Justice for a preliminary ruling:
‘(1) For the purposes of Articles 13 and 19 of [Regulation No 1768/92], is an authorisation a “first authorisation to place … on the market in the Community” if it is granted in pursuance of a national law which is compliant with [Directive 65/65], or is it necessary that it be established in addition that, in granting the authorisation in question, the national authority followed an assessment of data as required by the administrative procedure laid down in that directive?
(2) For the purposes of Articles 13 and 19 of [Regulation No 1768/92], does the expression “first authorisation to place … on the market in the Community” include authorisations which had been permitted by national law to co-exist with an authorisation regime which complies with [Directive 65/65]?
(3) Is a product which is authorised to be placed on the market for the first time in the EEC without going through the administrative procedure laid down in [Directive 65/65] within the scope of [Regulation No 1768/92] as defined by Article 2?
(4) If not, is an SPC granted in respect of such a product invalid?’Today's ruling runs as follows:
"1. Article 2 of Council Regulation ...1768/92 ... must be interpreted as meaning that a product, such as that at issue in the main proceedings, which was placed on the market in the European Community as a medicinal product for human use before obtaining a marketing authorisation in accordance with Council Directive 65/65 ... and, in particular, without undergoing safety and efficacy testing, is not within the scope of Regulation ...1768/92, as amended, and may not, therefore, be the subject of a supplementary protection certificate.The Court's ruling is, by ECJ standards, unusually short and to-the-point for an intellectual property ruling. The SPC Blog's post on the Advocate General's Opinion, on which the Court's ruling was based, can be read here.
2. A supplementary protection certificate granted for a product outside the scope of Regulation No 1768/92, as amended, as that scope is defined in Article 2 of that regulation, is invalid".
Labels:
ECJ reference,
Memantine,
Synthon
Subscribe to:
Posts (Atom)







